120 related articles for article (PubMed ID: 34000859)
1. Targeted PD-L1 PLGA/liposomes-mediated luteolin therapy for effective liver cancer cell treatment.
Cao X; Wang B
J Biomater Appl; 2021 Nov; 36(5):843-850. PubMed ID: 34000859
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of rMETase-Loaded Stealth PLGA/Liposomes Modified with Anti-CAGE scFV for Treatment of Gastric Carcinoma.
Xin L; Caot JQ; Liu C; Zeng F; Cheng H; Hu XY; Shao JH
J Biomed Nanotechnol; 2015 Jul; 11(7):1153-61. PubMed ID: 26307838
[TBL] [Abstract][Full Text] [Related]
3. Luteolin-loading of Her-2-poly (lactic-co-glycolic acid) nanoparticles and proliferative inhibition of gastric cancer cells via targeted regulation of forkhead box protein O1.
Ding J; Li Q; He S; Xie J; Liang X; Wu T; Li D
J Cancer Res Ther; 2020; 16(2):263-268. PubMed ID: 32474511
[TBL] [Abstract][Full Text] [Related]
4. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
Lee CK; Atibalentja DF; Yao LE; Park J; Kuruvilla S; Felsher DW
Nanotheranostics; 2022; 6(3):243-255. PubMed ID: 35145835
[No Abstract] [Full Text] [Related]
6. Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
Phung CD; Nguyen HT; Choi JY; Pham TT; Acharya S; Timilshina M; Chang JH; Kim JH; Jeong JH; Ku SK; Choi HG; Yong CS; Kim JO
J Control Release; 2019 Dec; 315():126-138. PubMed ID: 31672625
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-L1-modified and ATRA-loaded nanoparticles for immuno-treatment of oral dysplasia and oral squamous cell carcinoma.
Chen XJ; Zhang XQ; Tang MX; Liu Q; Zhou G
Nanomedicine (Lond); 2020 Apr; 15(10):951-968. PubMed ID: 32255397
[No Abstract] [Full Text] [Related]
8. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
[TBL] [Abstract][Full Text] [Related]
9. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced.
Song X; Wang J; Xu Y; Shao H; Gu J
Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022
[TBL] [Abstract][Full Text] [Related]
10. Effects of surface modification of As
Song X; You J; Shao H; Yan C
Colloids Surf B Biointerfaces; 2018 Sep; 169():289-297. PubMed ID: 29793091
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma.
Xin L; Zhang HT; Yang WF; Li YF; Liu C
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29229675
[TBL] [Abstract][Full Text] [Related]
12. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
Jiang ZB; Wang WJ; Xu C; Xie YJ; Wang XR; Zhang YZ; Huang JM; Huang M; Xie C; Liu P; Fan XX; Ma YP; Yan PY; Liu L; Yao XJ; Wu QB; Lai-Han Leung E
Cancer Lett; 2021 Sep; 515():36-48. PubMed ID: 34052328
[TBL] [Abstract][Full Text] [Related]
13. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine.
Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F
Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.
Zhao B; Dong Z; Liu W; Lou F; Wang Q; Hong H; Wang Y
J Nanobiotechnology; 2021 May; 19(1):124. PubMed ID: 33933077
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.
Sasaki K; Nishina S; Yamauchi A; Fukuda K; Hara Y; Yamamura M; Egashira K; Hino K
Cell Mol Gastroenterol Hepatol; 2021; 11(3):739-762. PubMed ID: 33191170
[TBL] [Abstract][Full Text] [Related]
16. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N
J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
[TBL] [Abstract][Full Text] [Related]
17. PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan.
Emami J; Maghzi P; Hasanzadeh F; Sadeghi H; Mirian M; Rostami M
Pharm Dev Technol; 2018 Jan; 23(1):41-54. PubMed ID: 28608760
[TBL] [Abstract][Full Text] [Related]
18. Engineered nanomedicine for myeloma and bone microenvironment targeting.
Swami A; Reagan MR; Basto P; Mishima Y; Kamaly N; Glavey S; Zhang S; Moschetta M; Seevaratnam D; Zhang Y; Liu J; Memarzadeh M; Wu J; Manier S; Shi J; Bertrand N; Lu ZN; Nagano K; Baron R; Sacco A; Roccaro AM; Farokhzad OC; Ghobrial IM
Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10287-92. PubMed ID: 24982170
[TBL] [Abstract][Full Text] [Related]
19. Vitamin E TPGS modified liposomes enhance cellular uptake and targeted delivery of luteolin: An in vivo/in vitro evaluation.
Li J; Cheng X; Chen Y; He W; Ni L; Xiong P; Wei M
Int J Pharm; 2016 Oct; 512(1):262-272. PubMed ID: 27545748
[TBL] [Abstract][Full Text] [Related]
20. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.
Gu F; Zhang L; Teply BA; Mann N; Wang A; Radovic-Moreno AF; Langer R; Farokhzad OC
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2586-91. PubMed ID: 18272481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
